Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Wyeth Research Division of Wyeth Pharmaceuticals Inc
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
To evaluate the safety and to determine the maximum tolerated dose (MTD), if reached, of TRU 015 in subjects with relapsed or refractory B cell NHL.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, FLEXIBLE-DOSE STUDY OF DVS-233 SR AND VENLAFAXINE ER IN ADULT OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The study objective is to compare the antidepressant efficacy and safety of DVS-233 SR with those of placebo in adult outpatients with MDD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
Estudio de Fase I/II de HKI-272 en combinación con trastuzumab (Herceptin) en sujetos con cáncer de mama avanzado A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer
Primary objectives: Part 1: To assess the safety and tolerability, and to define the MTD of orally administered HKI-272 in combination with trastuzumab in subjects with advanced breast cancer. Part ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom
- To demonstrate that the immune response induced by NeisVac-C or Pediacel given with 13vPnC is noninferior to the immune response induced by NeisVac-C or Pediacel given with 7vPnC when measured 1 mon...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Phase 2, Multicenter, Randomized, Active-Controlled, Parallel-Group, Dose-Finding and Safety Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) in Subjects With Decreased Bone Mineral Density
The primary objective of this study is to show increased BMD of the proximal femur (total hip BMD) after injection of rhBMP-2/CPM (either 1.0 mg/mL or 2.0 mg/mL) as an adjunct to systemic osteoporosis...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc, Clinical Research and Development
Update Il y a 4 ans
A 10-MONTH OPEN-LABEL EVALUATION OF THE LONG-TERM SAFETY OF DVS-233 SR IN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER
The primary study objective is to evaluate the long-term safety of DVS-233 SR during open-label treatment of outpatients with Major Depressive Disorder (MDD).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction in Subjects with Chronic Non-Malignant Pain
The primary objectives are: 1) To establish the dose-response relationship of MOA-728 by observing spontaneous bowel movements, and to establish appropriate doses to take into confirmatory phase 3 stu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company
Update Il y a 4 ans
An Open-label, Single-Arm, Phase 2 Study of Inotuzumab Ozogamicin Plus Rituximab in Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible for Autologous Stem Cell Transplantation
To evaluate efficacy and safety of inotuzumab ozogamicin in combination with rituximab when used as induction therapy prior to consolidation with HD chemo and aSCT in subjects with relapsed/refractory...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMENT AND POST TREATMENT IN REPRODUCTIVE-AGED WOMEN
-To evaluate the superiority of ERB-041 relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in reproductive-aged women using the Biber...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Wyeth Research Division of Wyeth Pharmaceuticals Inc
Update Il y a 4 ans
A 4-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE PRELIMINARY EFFICACY, SAFETY, AND PHARMACOKINETICS OF PPM-204 ADMINISTERED ORALLY TO TREATMENT-NAÏVE SUBJECTS WITH TYPE II DIABETES MELLITUS
To determine the glucose lowering effects of PPM-204 in subjects with type 2 diabetes mellitus.
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
Next